Medicilon Logo
|
search icon search icon language icon contact icon menu icon
Medicilon Logo
|
search icon close search icon language icon contact icon menu icon
logo icon CN
Contact Us
Close Button
Message
Back To Top
Online Message×
Click switch
Close Button
Medicilon's News information
News information

Xuanzhu Biotech Announced the Clinical Trial Approval of XZP-5610

2021-02-08
|
Page View:

Jan.27, 2021 – Xuanzhu Biotech announced that their XZP-5610, a new treatment for NASH (non-alcoholic steatohepatitis), was approved of clinical trials by China NMPA. XZP-5610 was the 14th innovative medicine that was approved of clinical trials. XZP is one small molecule agonist with high efficiency, high selectivity and novel structure that can significantly improve the steatosis, inflammation and fibrosis of the NASH animal model, with good pharmacokinetic properties and excellent safety. It is expected to be used in clinical practice and effectively treat NASH.

Xuanzhu Biotech
Xuanzhu Biotech Announced the Clinical Trial Approval of XZP-5610

During the preclinical R&D, Medicilon was honored to participate in the pharmacokinetics tests and safety evaluation. Medicilon’s team delivered the part of results with profession and efficiency.

Return
Relevant newsRelevant news